KR20030094097A - 플라비바이러스 감염의 치료 - Google Patents

플라비바이러스 감염의 치료 Download PDF

Info

Publication number
KR20030094097A
KR20030094097A KR10-2003-0035627A KR20030035627A KR20030094097A KR 20030094097 A KR20030094097 A KR 20030094097A KR 20030035627 A KR20030035627 A KR 20030035627A KR 20030094097 A KR20030094097 A KR 20030094097A
Authority
KR
South Korea
Prior art keywords
virus
flavivirus
effective amount
ribavirin
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR10-2003-0035627A
Other languages
English (en)
Korean (ko)
Inventor
추-안 휴
유안-친 차이
더-렌 황
Original Assignee
내셔날 헬스 리서치 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 내셔날 헬스 리서치 인스티튜트 filed Critical 내셔날 헬스 리서치 인스티튜트
Publication of KR20030094097A publication Critical patent/KR20030094097A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/245—Bismuth; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Packages (AREA)
KR10-2003-0035627A 2002-06-03 2003-06-03 플라비바이러스 감염의 치료 Withdrawn KR20030094097A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38503102P 2002-06-03 2002-06-03
US60/385,031 2002-06-03

Publications (1)

Publication Number Publication Date
KR20030094097A true KR20030094097A (ko) 2003-12-11

Family

ID=29550193

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-0035627A Withdrawn KR20030094097A (ko) 2002-06-03 2003-06-03 플라비바이러스 감염의 치료

Country Status (7)

Country Link
EP (1) EP1369120B1 (https=)
JP (1) JP2004131466A (https=)
KR (1) KR20030094097A (https=)
CN (1) CN1251687C (https=)
AT (1) ATE353658T1 (https=)
DE (1) DE60311702T2 (https=)
TW (1) TWI274585B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090058423A (ko) * 2007-12-04 2009-06-09 심형섭 소디움 메타아르세나이트를 함유하는 ｃ형 바이러스성 간염치료용 조성물
RU2518314C2 (ru) * 2012-08-30 2014-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Способ и средство активации irf-3 для лечения и профилактики заболеваний, вызываемых (+) phk-содержащими вирусами
TWI605822B (zh) * 2015-04-09 2017-11-21 高雄醫學大學 酪梨萃取物、ａｖｏｃａｄｅｎｏｌ Ｂ及（２Ｒ，４Ｒ）－１，２，４－三羥基十七碳－１６－炔的用途，以及包含酪梨萃取物之保健食品
EP3815699A1 (en) * 2019-10-28 2021-05-05 Technische Universität München New means and methods for therapy and diagnosis of adenoviral infection
IL295648A (en) * 2020-02-16 2022-10-01 Komipharm Int Australia Pty Ltd treatment method

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9214419D0 (en) * 1992-07-07 1992-08-19 Concannon Peter Biocidal agents
JPH0769903A (ja) * 1993-07-01 1995-03-14 Hatsuchiyou:Kk 抗ヒト免疫不全ウイルス剤およびエイズ治療薬
WO1995011033A1 (en) * 1993-10-22 1995-04-27 Commonwealth Scientific And Industrial Research Organisation Polyoxometallates in the treatment of flavivirus infections
FR2786103A1 (fr) * 1998-10-30 2000-05-26 Assist Publ Hopitaux De Paris Utilisation de trioxyde d'arsenic pour la preparation d'un medicament destine a traiter les affections neoplastiques du tissu hematopoietique chez un mammifere et nouvelle composition pharmaceutique
JP4420997B2 (ja) * 1999-02-08 2010-02-24 利博 山瀬 抗ウィルス剤
AU4463300A (en) * 1999-04-19 2000-11-02 Schering Corporation Hcv combination therapy, containing ribavirin in association with antioxidants
JP2001233719A (ja) * 1999-12-13 2001-08-28 Natl Inst Of Advanced Industrial Science & Technology Meti 殺菌材および殺菌方法
WO2001049302A1 (en) * 2000-01-06 2001-07-12 Marantech Holding, Llc Compositions and methods for facilitating skin growth and managing skin conditions
US7744867B2 (en) * 2001-05-31 2010-06-29 The Cleveland Clinic Foundation PTPase inhibitors and method of using same

Also Published As

Publication number Publication date
JP2004131466A (ja) 2004-04-30
DE60311702D1 (de) 2007-03-29
DE60311702T2 (de) 2007-10-31
EP1369120A1 (en) 2003-12-10
CN1483413A (zh) 2004-03-24
CN1251687C (zh) 2006-04-19
TW200307558A (en) 2003-12-16
ATE353658T1 (de) 2007-03-15
TWI274585B (en) 2007-03-01
EP1369120B1 (en) 2007-02-14

Similar Documents

Publication Publication Date Title
USRE47404E1 (en) Viral hepatitis treatment
JP5539363B2 (ja) インターフェロンおよびリバビリンとのｈｃｖｎｓ３プロテアーゼ阻害剤の組合せ
JP2013082726A (ja) 鉄が病因に関与する肝臓疾患の処置
CN103096891A (zh) 利用羟氯喹或羟氯喹和抗病毒剂的组合治疗丙型肝炎病毒相关疾病
ME00056B (me) Kombinacija kombrestatina i anti-kancer agensa
US8664268B2 (en) Gallium compositions for the treatment of liver cancer and methods of use
KR20230043598A (ko) 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염 및 항바이러스제를 유효성분으로 함유하는 코로나바이러스감염증-19(covid-19) 치료용 조성물
KR20030094097A (ko) 플라비바이러스 감염의 치료
TW201630597A (zh) 巴豆酯組成物及用於治療或減少血球細胞減少期間之用途
US6946125B2 (en) Methods of treating West Nile virus infection
RU2417083C2 (ru) Применение активаторов растворимой гуанилатциклазы для лечения острых и хронических легочных заболеваний
WO2008004653A1 (en) Prophylactic or therapeutic agent for viral disease
US20200163971A1 (en) Imeglimin for preventing and/or treating hepatocellular carcinoma
CN115634228B (zh) 嘌呤合成抑制剂在制备治疗缺血和缺血再灌注损伤药物中的应用
JPWO2006033453A1 (ja) インターフェロン作用物質の活性増強剤
Yoshimura et al. Gemcitabine/carboplatin in a modified 21-day administration schedule for advanced-stage non-small-cell lung cancer
WO2009084732A1 (ja) インターフェロン・リバビリン併用療法における副作用軽減剤
JP2004155777A (ja) Ｃ型慢性肝炎治療剤
US20120100105A1 (en) Agent and method for treating refractory chronic hepatitis c
Farouq et al. The Effect Of Antioxidants On The Side Effects Of Pegylated Interferon/Ribavirin Combination Therapy In Patients With Chronic Hepatitis C
JP2011051898A (ja) インターフェロン・リバビリン併用療法における副作用軽減剤
JP2011051897A (ja) インターフェロン・リバビリン併用療法における副作用軽減剤

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20030603

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid